Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-162

Hi Greevas,

Yes, I agree, our collaboration with RenovoRx and its TAMP platform has definitely slipped under the radar.
This could be due to that fact that it is still pre-clinical and all that the impatient punters want right now are
registrational trials (and results). Of course that would be nice, but its not how it works in trials of this nature.

Personally, I am watching this one like a hawk, and as Nick confirms, the very nature of a pancreatic cancer,
residing in a poorly vascularised area, creates unbelievable challenges.

If indeed the TAMP platform can deliver a good dose of our virus to the 'sweet spot', then look out. We will
be talking 'game changer'.

If IMU are looking to acquire this platform, the first we will know will be via an ASX announcement, as it
should be. Personally, I think it unlikely ... but I didn't see Azel-cell deal coming, so what would I know?

Glad to see others are following this and that Nick has followed up on your question. He is excellent in this
way, a great asset to the company.

As always, opinion only.